A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Patients with an allergy to iodine based intravenous contrast cannot undergo a CT scan with
contrast, unless they are premedicated. Premedication can result in a delay in diagnosis,
that can be significant with acute conditions such as Pulmonary embolism.
The investigators are evaluating the use of Gadolinium as an alternative contrast agent in
CT. Gadolinium has been used extensively in MRI exams but the dose that is used is not
sufficient to provide good enhancement on CT. Dual Energy CT is a new technology that has
better sensitivity to lower doses of intravenous contrast and the investigators aim to study
its effectiveness in improving the enhancement with Gadolinium. The investigators will
compare enhancement of Iodine with enhancement of Gadolinium during Dual Energy CT, to assess
the possibility that Gadolinium could be used as an alternative for patients who are
suspected of having Pulmonary embolism. They will recruit up to 50 patients who are having a
routine Chest CT during treatment for a malignancy and administer Gadolinium contrast and
Iodine contrast during a chest CT exam. The enhancement with the two agents can be compared.